Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)
Tecentriq ® (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news